ATOSSA THERAPEUTICS, INC. - 10-Q Summary
Business Context and Reporting Period
Company: Atossa Therapeutics, Inc. (ATOS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: A clinical-stage biopharmaceutical company focused on developing (Z)-endoxifen, a proprietary oral agent for breast cancer and rare diseases (Duchenne muscular dystrophy, McCune-Albright Syndrome). The company has no commercial revenue and relies on capital markets for funding.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(8,491) | $(18,080) | $(15,141) |
| Net Loss Per Share (Basic/Diluted) | $(0.95) | $(2.06) | $(1.76) |
| Operating Expenses | $8,694 | $18,564 | $16,454 |
| Cash & Cash Equivalents (End of Period) | $26,094 (as of June 30, 2026) | ||
| Working Capital | $25,559 (as of June 30, 2026) | ||
| Net Cash Used in Operating Activities | $(19,225) (Six Months 2026) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by $2.1 million (13%) for the six months ended June 30, 2026, compared to the prior year period. This was driven primarily by a $2.6 million increase in General and Administrative (G&A) professional fees, largely due to legal costs associated with settled patent litigation and SEC compliance.
- Research & Development (R&D): R&D expenses remained relatively flat ($9.7 million vs. $9.7 million) for the six-month period. Clinical trial enrollment costs increased, offset by a decrease in preclinical expenses.
- Capital Structure: The company completed a 1-for-15 reverse stock split on February 2, 2026. All share and per-share data have been retroactively restated.
- Financing Activity: In June 2026, the company raised approximately $4.0 million in net proceeds via a registered direct offering of common stock and warrants. Additionally, $21,000 was raised through an At-the-Market (ATM) offering.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern. Management expects existing resources to be insufficient to fund planned operations for the next 12 months and anticipates the need for additional capital.
- Clinical Pipeline:
- Karisma-(Z)-endoxifen: Top-line durability data expected in Q3 2026.
- I-SPY 2: Data expected in the second half of 2026.
- EVANGELINE: Enrollment completed as of June 30, 2026.
- Regulatory Designations: Received Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS).
- Legal Proceedings: Settled patent challenges with Intas Pharmaceuticals in April 2026, resolving Post Grant Review and Inter Partes Review petitions. Patents remain enforceable.
- Risks: Key risks include the inability to raise additional capital, failure of clinical trials, regulatory delays, and potential loss of Australian R&D tax rebates (a $1.1 million liability is accrued).
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for the next capital raise given the "substantial doubt" disclosure and the expectation that current cash ($26.1M) will not cover 12 months of operations.
- Legal Settlement Terms: Review the specific terms of the April 2026 settlement with Intas Pharmaceuticals to ensure no hidden financial obligations or restrictive covenants remain.
- Patent Portfolio: Confirm the status of the remaining patent portfolio post-settlement and the timeline for expiration (currently projected through 2038).
- Clinical Data Readiness: Monitor the release of top-line durability data from the Karisma study (expected Q3 2026) and I-SPY 2 data (expected H2 2026) as critical value drivers.
- Australian Tax Liability: Assess the risk associated with the $1.1 million accrued liability regarding Australian R&D tax rebates and the potential for further adjustments.